Berlin I, Bisserbe J C, Eiber R, Balssa N, Sachon C, Bosquet F, Grimaldi A
Department of Clinical Pharmacology, INSERM Unité 302, Hôpital Pitié-Salpêtrière, Paris, France.
Diabetes Care. 1997 Feb;20(2):176-8. doi: 10.2337/diacare.20.2.176.
To investigate the presence of psychiatric disorders and symptoms in type I diabetic patients and to identify those that may influence metabolic control as assessed by GHb levels.
This was a cross-sectional study. One hundred and two consecutive patients with type I diabetes who were regular outpatient visitors of a diabetology department were evaluated. The psychiatric assessments included self-rating questionnaires (General Health Questionnaire and Fear Questionnaire) and observer-rating questionnaires (Montgomery-Asberg Depression Rating Scale [MADRS] and Mini International Interview). Diabetic characteristics were assessed by a structured interview. The observer was blind to the diabetic characteristics of the patients.
Type I diabetic patients with GHb levels > or = 8% had higher psychological distress, scored significantly higher for symptoms of agoraphobia and for fear of blood and injury, had substantially higher levels of anxiety-depression, and performed significantly fewer blood glucose measurements per day. They did not differ in MADRS score from patients with GHb levels < 8%. Multivariate analysis showed that GHb was positively associated with the total score of phobic symptoms and the level of anxiety-depression and inversely associated with the number of daily blood glucose measurements. These factors explained 41% of the variance of GHb. The inverse relationship between GHb and the number of blood glucose measurements per day was mainly influenced by the fear of blood and injury. Patients with high scores for the fear of blood and injury performed fewer blood glucose measurements and had poorer glycemic control; conversely, subjects without fear of blood and injury performed more daily blood glucose measurements and had better glycemic control.
Phobic symptoms are frequent in patients with type I diabetes. The intensity of phobic symptoms and anxiety-depression negatively influences metabolic control. Increased fear of blood and injury may lead some patients to perform few home blood glucose measurements and may result in poorer glycemic control. This suggests that, by decreasing the fear of blood, injury, and injection, metabolic control may be improved.
调查1型糖尿病患者精神障碍及症状的存在情况,并确定那些可能影响糖化血红蛋白(GHb)水平所评估的代谢控制的因素。
这是一项横断面研究。对某糖尿病科连续120例定期门诊就诊的1型糖尿病患者进行了评估。精神评估包括自评问卷(一般健康问卷和恐惧问卷)和他评问卷(蒙哥马利-阿斯伯格抑郁评定量表[MADRS]和简易国际访谈)。通过结构化访谈评估糖尿病特征。观察者对患者的糖尿病特征不知情。
GHb水平≥8%的1型糖尿病患者心理困扰更严重,广场恐惧症症状及对血液和受伤的恐惧得分显著更高,焦虑抑郁水平显著更高,且每天进行的血糖测量次数显著更少。他们的MADRS得分与GHb水平<8%的患者无差异。多变量分析显示,GHb与恐惧症状总分及焦虑抑郁水平呈正相关,与每日血糖测量次数呈负相关。这些因素解释了GHb变异的41%。GHb与每日血糖测量次数之间的负相关主要受对血液和受伤的恐惧影响。对血液和受伤恐惧得分高的患者血糖测量次数更少,血糖控制更差;相反,无血液和受伤恐惧的受试者每日血糖测量次数更多,血糖控制更好。
恐惧症状在1型糖尿病患者中很常见。恐惧症状和焦虑抑郁的严重程度对代谢控制有负面影响。对血液和受伤的恐惧增加可能导致一些患者在家中很少进行血糖测量,并可能导致血糖控制较差。这表明,通过减少对血液、受伤和注射的恐惧,可能改善代谢控制。